Eisai Inc.
Clinical trials sponsored by Eisai Inc., explained in plain language.
Now part of
Eisai Co., Ltd.
ESAIY
OTC
A pharmaceutical company focused on neurology and oncology, subsidiary of Eisai Co., Ltd.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new drug play nice with common medicines? a trial investigates Results expected Nov 2026 (estimated)
- Double attack on Alzheimer's: new drug combo targets tau and amyloid Results expected Dec 2026 (estimated)
- Mining medical claims: a smarter way to spot Alzheimer's complications? Results expected Dec 2026 (estimated)
- New pill aims to keep narcolepsy patients awake and safe Results expected Feb 2027 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Mar 2027 (estimated)